Strategies for pediatric drug evaluation: A view from the trenches

Drug Information Journal

Volumn 30, Issue 4, 1996, Pages 1149-1162

  Wilson, John T ^a  

^a LOUISIANA STATE UNIV MEDICAL CENTER   (United States)

Author keywords

Children; Clinical trials; Ethical guidelines; Pediatric labeling; Pediatric regulations

Indexed keywords

AMPICILLIN; METHOTREXATE; ORPHAN DRUG; PLACEBO;

CHILD; CHILD CARE; CLINICAL PROTOCOL; CLINICAL TRIAL; DRUG APPROVAL; DRUG DELIVERY SYSTEM; DRUG INDICATION; DRUG INDUSTRY; DRUG LABELING; DRUG LEGISLATION; DRUG PROGRAM; DRUG RESEARCH; DRUG SCREENING; FOOD AND DRUG ADMINISTRATION; HEALTH ECONOMICS; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; INTRATRACHEAL DRUG ADMINISTRATION; MEDICAL ETHICS; MEDICAL SOCIETY; MEDICOLEGAL ASPECT; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PHASE 4 CLINICAL TRIAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECTAL DRUG ADMINISTRATION; REVIEW; TRANSDERMAL DRUG ADMINISTRATION;

EID: 0029827507     PISSN: 00928615     EISSN: None     Source Type: Journal    
DOI: 10.1177/009286159603000434     Document Type: Review

References (15)

1. Yaffe SJ, Aranda JV. Introduction and Historical Perspectives. In Yaffe SJ, Aranda JV (ed). Pediatric Pharmacology, Therapeutic Principles in Practice. Philadelphia: W.B. Saunders Co.; 1980, 3-9.
2. Shirkey H. Therapeutic orphans. J Pediatr. 1968; 72:119-120.A.
3. Wilson JT. Pragmatic assessment of medicines available for young children and pregnant or breast-feeding women. In Morselli et al. (eds). Basic and therapeutic aspects of perinatal pharmacology. New York: Raven Press; 1977;76-112.
4. Gilman JT, Gal P. Pharmacokinetic and pharmacodynamic data collection in children and neonates. Clin Pharmacokinet. 1992;23(1):1-9.
5. Kearns GL, Reed MD. Clinical pharmacokinetics in infants and children. Clin Pharmacokinet. 1989; 17(Suppl. 1):29-67.
6. Grodin MA, Alpert JJ. Children as participants in medical research. Pediatr Clin North Am. 1988; 35(6):1389-1401.
7. Guidelines for the Ethical Conduct of Studies to Evaluate Drugs in Pediatric Populations, Committee on Drugs. Pediatrics. 1995;95(2):286-294.
8. Additional protection for children involved as subjects in research. Federal Register. Mar 8, 1983; 48:114-117.
9. Kauffman RE, Kearns GL. Pharmacokinetic studies in pediatric patients. Clin Pharmacokinet. 1992; 23(1):10-29.
10. American Academy of Pediatrics Committee on Drugs. General guidelines for the evaluation of drugs to be approved for use during pregnancy and for treatment of infants and children: A report of the Committee on Drugs, American Academy of Pediatrics to the Food and Drug Administration, US Department of Health, Education and Welfare, pp. 1-40, American Academy of Pediatrics Chicago; 1974.
11. Federal Register, Part II, Department of Health and Human Services, Food and Drug Administration 21 CRF Part 201. Specific requirements on content and formal of labeling for human prescription drugs; Revision of "Pediatric Use" Subsection in the Labeling; Final Rule. December 13, 1994.
12. Kauffman RE. Drug trials in children: Ethical, legal, and practical issues. J Clin Pharmacol. 1994; 34:296-299.
13. Wilson JT. Pediatric pharmacology: Who will test the drugs? J Pediatr. 1972;80(5):855-857.
14. Wilson JT. Pediatric pharmacology: The path clears for a noble mission. J Clin Pharmacol. 1993; 33(3):210-212.
15. Wilson JT, Kearns GL, Murphy D, Yaffe SJ. Pediatric labeling requirements. Clin Pharmacokinet. 1994;26(4):308-325.